Market Cap 7.11M
Revenue (ttm) 2.00M
Net Income (ttm) -3.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -153.00%
Debt to Equity Ratio 0.00
Volume 22,200
Avg Vol 452,692
Day's Range N/A - N/A
Shares Out 3.34M
Stochastic %K 21%
Beta 1.32
Analysts Strong Buy
Price Target $4.00

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebi...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 327 8778
Address:
245 First Street, Riverview II, 18th Floor, Cambridge, United States
StockTwitsGhost
StockTwitsGhost Oct. 25 at 8:55 PM
$CYCN CVCO announces a Phase 2 Olinciguat trial with Karolinska University Hospital, while Tony Colasin is simultaneously is facilitating a CVCO Series A raise. Epizon Pharma is revealed as a wholly owned CVCO subsidiary, co-founded by billionaire John Rudey. October 22 was the hard date for Olinciguat licensing, which should’ve started the material news clock. Sun/Mon this week the CVCO website went to “scheduled maintenance”, Colasin updated his LinkedIn to CVCO, and he reveals Epizon out of stealth mode. Too many “coincidences” lining up. Next week could get loud. 15% CVCO/Epizon stake and $2M upfront? Ben what do you think? @skyrockets_Inc
0 · Reply
EZYME22
EZYME22 Oct. 25 at 2:19 PM
$CYCN its almost halloween zombies awaken to take shorts
1 · Reply
herowon
herowon Oct. 25 at 1:53 PM
$CYCN is the stock dead?
0 · Reply
herowins
herowins Oct. 23 at 11:27 AM
$CYCN fair price : $0
0 · Reply
EZYME22
EZYME22 Oct. 23 at 1:36 AM
$CYCN lets see how tomm goes the five day material news clock is officially ticking on CVCO?
2 · Reply
herowins
herowins Oct. 23 at 12:03 AM
$CYCN fair price target : $ 1
1 · Reply
herowins
herowins Oct. 22 at 10:33 AM
1 · Reply
Mr_Pithy
Mr_Pithy Oct. 22 at 8:10 AM
$CYCN Praliciguat - Alive and well?
1 · Reply
herowins
herowins Oct. 22 at 12:09 AM
$CYCN target value : 1.5
1 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 21 at 6:42 PM
$CYCN Day 29 since Tisento last update. Highly unusual and this oddly mirrors Cyclerion’s last update. Tisento has near term catalysts with its combination of clinical progress, regulatory traction, and partnership readiness. The current blackout in public communication may signal that dealmaking or Series B efforts are already underway. This could explain Cyclerion’s painfully obvious lack of color on how they’ll fund the TRD program. CVCO is also refreshing its public facing platforms. Colasin recently updated his LinkedIn profile to reflect CVCO on the front burner, no longer simmering on the back burner.
0 · Reply
Latest News on CYCN
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

Sep 24, 2025, 12:53 PM EDT - 4 weeks ago

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call


Regina Graul, Ph.D., Promoted to Chief Executive Officer

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer


Cyclerion Appoints Regina Graul, Ph.D., as President

Dec 4, 2023, 8:00 AM EST - 2 years ago

Cyclerion Appoints Regina Graul, Ph.D., as President


Cyclerion Announces Reverse Stock Split

May 15, 2023, 1:00 PM EDT - 2 years ago

Cyclerion Announces Reverse Stock Split


Cyclerion Therapeutics to Host Pipeline Update Webinar

Apr 20, 2021, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Host Pipeline Update Webinar


StockTwitsGhost
StockTwitsGhost Oct. 25 at 8:55 PM
$CYCN CVCO announces a Phase 2 Olinciguat trial with Karolinska University Hospital, while Tony Colasin is simultaneously is facilitating a CVCO Series A raise. Epizon Pharma is revealed as a wholly owned CVCO subsidiary, co-founded by billionaire John Rudey. October 22 was the hard date for Olinciguat licensing, which should’ve started the material news clock. Sun/Mon this week the CVCO website went to “scheduled maintenance”, Colasin updated his LinkedIn to CVCO, and he reveals Epizon out of stealth mode. Too many “coincidences” lining up. Next week could get loud. 15% CVCO/Epizon stake and $2M upfront? Ben what do you think? @skyrockets_Inc
0 · Reply
EZYME22
EZYME22 Oct. 25 at 2:19 PM
$CYCN its almost halloween zombies awaken to take shorts
1 · Reply
herowon
herowon Oct. 25 at 1:53 PM
$CYCN is the stock dead?
0 · Reply
herowins
herowins Oct. 23 at 11:27 AM
$CYCN fair price : $0
0 · Reply
EZYME22
EZYME22 Oct. 23 at 1:36 AM
$CYCN lets see how tomm goes the five day material news clock is officially ticking on CVCO?
2 · Reply
herowins
herowins Oct. 23 at 12:03 AM
$CYCN fair price target : $ 1
1 · Reply
herowins
herowins Oct. 22 at 10:33 AM
1 · Reply
Mr_Pithy
Mr_Pithy Oct. 22 at 8:10 AM
$CYCN Praliciguat - Alive and well?
1 · Reply
herowins
herowins Oct. 22 at 12:09 AM
$CYCN target value : 1.5
1 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 21 at 6:42 PM
$CYCN Day 29 since Tisento last update. Highly unusual and this oddly mirrors Cyclerion’s last update. Tisento has near term catalysts with its combination of clinical progress, regulatory traction, and partnership readiness. The current blackout in public communication may signal that dealmaking or Series B efforts are already underway. This could explain Cyclerion’s painfully obvious lack of color on how they’ll fund the TRD program. CVCO is also refreshing its public facing platforms. Colasin recently updated his LinkedIn profile to reflect CVCO on the front burner, no longer simmering on the back burner.
0 · Reply
Bullbear1010101
Bullbear1010101 Oct. 21 at 5:32 PM
$CYCN Long term , 3-5 years who knows now seems destined for 2.00??
0 · Reply
herowins
herowins Oct. 21 at 12:37 PM
$CYCN target value today 2.00.
2 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 21 at 11:13 AM
$CYCN Last week, CVCO updated the pipeline section for Olinciguat, and their site is currently down for maintenance. Could this indicate that CVCO has finalized its raise and that the long-awaited licensing news is imminent? http://cvco-tx.com
2 · Reply
herowins
herowins Oct. 20 at 9:27 PM
1 · Reply
herowins
herowins Oct. 20 at 9:26 PM
1 · Reply
herowins
herowins Oct. 20 at 9:25 PM
1 · Reply
Mr_Pithy
Mr_Pithy Oct. 20 at 11:54 AM
$CYCN Please report @herowins to Stocktwits for stock price manipulation which is illegal, of course. heroloser has posted 33 times since September 25, 2025. All posts were “bearish.” All posts lacked a single fact in support of the opinion. Let’s not tolerate illegal and manipulative activities on this board. Thank you.
0 · Reply
herowins
herowins Oct. 20 at 10:46 AM
1 · Reply
herowins
herowins Oct. 19 at 2:14 AM
1 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 18 at 8:51 PM
$CYCN The silence from both Cyclerion and J Wood Capital in response to a letter sent to IR, Dr. Graul, Jason Wood, and David Liu is deeply concerning. At best, it reflects poor governance or investor relations; at worst, it suggests deliberate concealment. The fact that J Wood only filed its Schedule 13G after being publicly called out indicates a clear awareness of its disclosure obligations and a willingness to ignore SEC compliance until external pressure forced action. While only J Wood can explain the delay, possible reasons include negligence or incompetence in monitoring regulatory requirements, intentional concealment to avoid scrutiny or influence the stock without public awareness, or, more troublingly, potential coordination with Cyclerion to suppress timely disclosure—raising questions of collusion and serious fiduciary breaches. MORE COMPLAINTS ARE BEING FILED WITH STATE AND FEDERAL REGULATORS THIS WEEK.
2 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 18 at 5:46 PM
$CYCN March 2025 J Wood Cap acquired 181,818 shares CYCN representing over 5% of the company’s outstanding stock a threshold that typically requires prompt disclosure via SEC filings such as Schedule 13G or 13D within 10 days. However, no such filings were made for nearly seven months. Only after a concerned investor sent detailed letter in early October, raising the issue with both CYCN and J Wood and warning of potential SEC action, did J Wood file a Schedule 13G on October 18. This late filing appears to be an attempt to retroactively cure a clear violation of SEC rules under Section 13(d) of the Securities Exchange Act. The lack of timely disclosure undermines shareholder transparency and raises serious governance concerns. Shareholders should remain vigilant and consider filing complaints with the SEC or other regulatory bodies to protect their interests and ensure compliance is enforced. Silence or inaction in the face of such lapses threatens market integrity and investor trust.
1 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 18 at 5:32 PM
$CYCN J. Wood likely filed its Schedule 13G in response to pressure placed on both Cyclerion and J. Wood. A detailed letter addressing these concerns was sent to Cyclerion Investor Relations, CEO Dr. Andreas Graul, Jason Wood, and David Liu on October 7, 2025 (See Attached). No one responded. As a result, a formal complaint was submitted to the appropriate enforcement agencies. I will table this discussion here with a copy of the original letter. However, let me be clear: informed investors are watching, and they will no longer tolerate the manipulation of their investment in Cyclerion. While I am not directly accusing J. Wood or Cyclerion of manipulating CYCN stock, whatever is happening must stop—effective immediately. CYCN shareholders demand transparency. We expect timely and substantive updates on CVCO, Akebia, the MIT license financing, Tisento, and other material developments. If Dr. Graul is unwilling or unable to provide these updates, then the Board has a duty to act.
2 · Reply